It is uncertain how long catheter delivered percutaneous heart valves may last. In congenital cardiology, stenosis and regurgitation of right ventricular to pulmonary artery conduits and valves is common, leading to repeated operations for young patients with concomitant mortality and morbidity. It has also been unclear whether percutaneous pulmonary valves last as long as surgical pulmonary valves. When the current generation of the percutaneous pulmonary valve was first implanted in the United Kingdom from 2003, randomized trials were initially not performed, decided on a case-by-case basis in congenital cardiology, nor long-term registries kept. We describe three cases where such percutaneous heart valves have lasted up to 19 years. All valves were working without significant stenosis and minor degrees of regurgitation on long-term echocardiographic follow-up, patients being asymptomatic. This demonstrates that percutaneous pulmonary valves can achieve long-term durability and may prevent the need for otherwise high-risk surgery in congenital cardiac patients.

Download full-text PDF

Source
http://dx.doi.org/10.1002/ccd.30534DOI Listing

Publication Analysis

Top Keywords

percutaneous heart
12
heart valves
12
percutaneous pulmonary
12
pulmonary valves
12
valves
9
long-term durability
8
congenital cardiology
8
percutaneous
6
pulmonary
6
valves demonstrating
4

Similar Publications

Empagliflozin, a sodium-glucose cotransporter-2 (SGLT2) inhibitor, has garnered significant interest due to its potential cardiovascular benefits, particularly in patients experiencing acute myocardial infarction (AMI) who are undergoing primary percutaneous coronary intervention (PCI). This systematic review aims to evaluate the effectiveness of Empagliflozin in improving clinical outcomes in this patient population. A systematic review of randomized controlled trials (RCTs) was conducted to assess the effects of Empagliflozin on clinical outcomes in patients with AMI undergoing primary PCI.

View Article and Find Full Text PDF

Background: The vertical vein (VV) ligation during the total anomalous pulmonary venous return (TAPVR) correction is still controversial. Our study aimed to define the potential risk factors for VV persistence and their percutaneous occlusion.

Methods: The retrospective cohort study included 40 patients (26 males) with TAPVR treated at the tertiary referral center from 2005 to 2024.

View Article and Find Full Text PDF

Background And Objectives: The optimal timing for complete revascularization (CR) in patients with acute myocardial infarction (AMI) and multivessel disease (MVD) remain uncertain.

Methods: This post-hoc analysis of the FRAME-AMI trial included AMI patients with MVD ( = 549). They were classified into immediate ( = 329) and staged CR ( = 220) groups.

View Article and Find Full Text PDF

Coronary heart disease and type 2 diabetes mellitus (T2DM) often co-occur, presenting substantial health risks, particularly following acute myocardial infarction (AMI). While percutaneous coronary intervention (PCI) is a prevalent treatment, complications such as microvascular dysfunction may lead to heart failure, necessitating additional therapies. This editorial examines the emerging roles of sacubitril/valsartan and sodium-glucose co-transporter 2 inhibitors in managing post-PCI.

View Article and Find Full Text PDF

Introduction: Pericardial effusion (PE) is an abnormal accumulation of fluid in the pericardial space, which, if severe, is associated with high mortality. The causes are diverse, including infective and non-infective. Few studies have looked at the spectrum of severity and causes in Northern Nigeria.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!